Literature DB >> 1825638

Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra.

T M Dawson1, V L Dawson, F H Gage, L J Fisher, M A Hunt, J K Wamsley.   

Abstract

Interruption of the ascending dopamine neurons of the nigrostriatal pathway, by 6-hydroxydopamine (6-OHDA) lesion in rats, produced a significant loss of the dopamine transport complexes labeled with the phencyclidine derivative [3H]BTCP. This loss of dopamine innervation in the striatum was present at least 12 to 14 months after lesioning and was functionally manifested by ipsilateral rotation of the animals in response to amphetamine. In these same animals, in comparison to controls, there was a significant increase in the number (Bmax) of [3H]SCH 23390-labeled D-1 receptors in the striatum (36.7%) and the substantia nigra (35.1%) and a 54.4% increase in the number (Bmax) of [3H]sulpiride-labeled striatal D-2 receptors without an apparent change in affinity (Kd). Ten to twelve months after the transplantation of homologous fetal substantia nigra into the denervated striatum, there was a significant decrease in amphetamine-induced turning behavior. In these animals, there was an ingrowth of dopamine nerve terminals in the striatum as demonstrated by a return of [3H]BTCP binding. Accompanying this reinnervation was the normalization of D-1 and D-2 receptors to control values in the striatum as well as the return of D-1 receptors to prelesion densities in the substantia nigra. In a subgroup of transplanted rats, amphetamine continued to induce ipsilateral turning. In these animals both D-1 and D-2 receptors remained supersensitive. These results support the hypothesis that the functional recovery of transplanted animals is due, in part, to reinnervation of the striatum. In addition, long-term alterations in receptor density may be related to the behavioral deficits that are associated with the 6-OHDA-lesioned rat. Furthermore, dopamine receptor plasticity may play a role in the functional recovery of substantia nigra transplanted animals and graft viability seems to be a prerequisite for behavioral recovery as well as receptor normalization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825638     DOI: 10.1016/0014-4886(91)90095-t

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease.

Authors:  Jose A Rodríguez-Gómez; Jian-Qiang Lu; Iván Velasco; Seth Rivera; Sami S Zoghbi; Jeih-San Liow; John L Musachio; Frederick T Chin; Hiroshi Toyama; Jurgen Seidel; Michael V Green; Panayotis K Thanos; Masanori Ichise; Victor W Pike; Robert B Innis; Ron D G McKay
Journal:  Stem Cells       Date:  2006-12-14       Impact factor: 6.277

2.  Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.

Authors:  N Nakao; M Ogura; K Nakai; T Itakura
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

3.  Conditioning versus priming of dopaminergic grafts by amphetamine.

Authors:  L E Annett; P J Reading; D Tharumaratnam; D N Abrous; E M Torres; S B Dunnett
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

4.  Regulation of dopamine levels in intrastriatal grafts of fetal mesencephalic cell suspension: an in vivo voltammetric approach.

Authors:  H Moukhles; C Forni; A Nieoullon; A Daszuta
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

5.  Intrastriatal dopamine-rich grafts induce a hyperexpression of Fos protein when challenged with amphetamine.

Authors:  D N Abrous; E M Torres; L E Annett; P J Reading; S B Dunnett
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 6.  Neuronal Replacement as a Tool for Basal Ganglia Circuitry Repair: 40 Years in Perspective.

Authors:  Anders Björklund; Malin Parmar
Journal:  Front Cell Neurosci       Date:  2020-05-29       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.